Pharmaceuticals

Latest Updates of 9 Viva's Portfolio Companies

HONG KONG, June 2, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the succ...

2023-06-02 18:51 3145

TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA)

Company and Yale University Hospital seeking participants with GA for Phase 1 trials of medicine FDA-approved for other ailments NEW HAVEN, Conn., June 2, 2023 /PRNewswire/ -- TWi Biotechnology (TWiB), a clinical stage biopharmaceutical company specializing in development of repositioned drugs f...

2023-06-02 15:51 1849

NMPA accepted Akeso's ebronucimab (PCSK9) marketing application in two cardiovascular indications

HONG KONG, June 1, 2023 /PRNewswire/ -- Akeso Inc. (9926. HK, "Akeso") announced today thatChina's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for its fully human anti-PCSK9 monoclonal antibody ebronucimab (AK102) for 2 indications 1) primary hyper...

2023-06-02 11:43 1981

Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China

ROCKVILLE, Md. and SUZHOU, China, June 2, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2023-06-02 08:00 5597

EVERSANA Forms Strategic Alliance with China Resource Pharmaceutical Commercial Group to Bring New Novel Treatments to Patients Globally

BEIJING, June 2, 2023 /PRNewswire/ -- EVERSANA®, a leading provider of commercialization services to the global life sciences industry, today announced that it has established a strategic alliance with the China Resources Pharmaceutical Commercial Group, a leading pharmaceutical distribution ent...

2023-06-02 00:10 2778

Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

HONG KONG, Germantown, Md. and Suzhou, China, June 2, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today...

2023-06-02 00:06 6653

GenEros to Present Promising Results of GEC255 Phase I Clinical Trial for Advanced NSCLC Patients with KRAS G12C Mutation

HANGZHOU, China, June 1, 2023 /PRNewswire/ -- GenEros Biopharma Ltd. ("GenEros" or "the Company"), a biopharmaceutical company dedicated to discovering, developing, and commercializing novel medicines for diseases with unmet medical needs, will unveil the preliminary data from the phase I clinica...

2023-06-01 22:15 2321

YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA

GAITHERSBURG, Md., June 1, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...

2023-06-01 20:30 2600

Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors

SHANGHAI and HAYWARD, Calif., June 1, 2023 /PRNewswire/ -- IMPACT Therapeutics ("Impact"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, and Eikon Therapeutics ("Eikon"), a biotechnology company that is adv...

2023-06-01 20:30 2049

BIORCHESTRA Invited to Present Update on Central Nervous System Lead Program (BMD-001) and IV-Formulated siRNA Data at BIO2023 International Conference

* Presentation:"Successfully Achieving Intravenous (IV)-formulated RNA Delivery to the Brain, Evidence of Efficacy" scheduled for June 08, 2023, 12:00 p.m. ET, Room 104A * Pioneering IV-formulated inert drug delivery platform targeting neurodegenerative diseases * Lead program (BMD-001) adv...

2023-06-01 20:00 1951

Seegene Obtains IVDR Certification for 30 Diagnostic Assays

* Seegene certifies diagnostic assays for digestive, respiratory, women's diseases, and human papillomavirus to meet IVDR requirements * New regulation sets improved standards to ensure higher level of quality, safety, and reliability SEOUL, South Korea, June 1, 2023 /PRNewswire/ -- Seegene I...

2023-06-01 19:00 1858

Xinhua Silk Road: Activity to promote TCM cultural exchanges and cooperation between China and Luxembourg completes success

BEIJING, June 1, 2023 /PRNewswire/ -- An activity to promote traditional Chinese medicine (TCM) cultural exchanges and cooperation betweenChina and Luxembourg held recently at the Luxembourg Embassy in China achieved a complete success. A tea...

2023-06-01 17:37 1821

Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe

VIENNA, June 1, 2023 /PRNewswire/ -- Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, in its European core markets includin...

2023-06-01 17:18 3127

Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma

-  XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) ofAustralia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and in triple class refractory R/R MM. -  This inclusion b...

2023-06-01 10:09 2917

Xinhua Silk Road: Chinese Lingzhi brand Longevity Valley promotes inheritance of a century-old national treasure to Brunei foreign envoys

BEIJING, May 31, 2023 /PRNewswire/ -- A delegation of the renowned Chinese Lingzhi brand, Zhejiang Longevity Valley Botanical Co., Ltd, recently visited the Embassy ofBrunei Darussalam in China to showcase Chinese traditional culture and wisdom of health philosophy embedded in the brand toBrunei....

2023-06-01 09:47 1978

Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders

BRII-297, a first-of-its-kind treatment option for anxiety and depressive disorders, has the potential to enable greater therapeutic adherence and convenience for patients DURHAM, N.C. and BEIJING, June 1, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or...

2023-06-01 08:00 2406

Advances of Qilu Pharmaceutical's QL1706 in Clinical Research Presented at ASCO Annual Meeting

JINAN, China, June 1, 2023 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting. Four clinical research abstracts on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immun...

2023-06-01 00:55 2280

Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention

Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, May 31, 2023 /PRNewswire/ -- Actin...

2023-05-31 20:58 1970

Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction

- Caliway has initiated the subject recruitment in CBL-0204 Phase 2b study. - The study is expected to be completed in Q2 2024, and the topline results are anticipated in Q3 2024. TAIPEI, May 31, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals, a biopharmaceutical company focusing on breakthroug...

2023-05-31 20:15 2813

QBIOTICS TO PRESENT AT SACHS 9TH ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM AND THE BIO INTERNATIONAL CONVENTION

BRISBANE, Australia, May 31, 2023 /PRNewswire/ -- QBiotics Group Limited ( QBiotics), a clinical stage life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals is pleased to announce thatRichard Godfrey will present to potential partners and investors at t...

2023-05-31 19:00 2509
1 ... 54555657585960 ... 291

Week's Top Stories